Mangalam Drugs & Organics Complete Financial Statements
In FY2026, Mangalam Drugs & Organics (MANGALAM) reported revenue ₹67 Cr, net profit ₹-13 Cr and EPS ₹-8.48, with a net profit margin of -19.4% and ROE of -12.6%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Mangalam Drugs & Organics share price today.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
MANGALAM Revenue, Net Profit & EBITDA — Year-on-Year Growth
MANGALAM YoY (Mar 2025 vs Mar 2026) — revenue -8.2%, EBITDA -160.0%, expenses +15.9%. Review Mangalam Drugs & Organics price earnings to evaluate earnings-based valuation against sector peers.
MANGALAM Income Statement — Revenue, EBITDA & Net Profit
Mangalam Drugs & Organics revenue ₹67 Cr, EBITDA ₹-6 Cr, net profit ₹-13 Cr, EPS ₹-8.48 (2026) — net profit margin -19.4%. Explore Mangalam Drugs & Organics intrinsic price to estimate fundamental worth using multiple valuation models.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 49 | 73 | 57 | 59 | 80 | 102 | 77 | 89 | 97 |
| Expenses | 73 | 52 | 63 | 62 | 60 | 71 | 91 | 68 | 80 | 90 |
| EBITDA | -6 | -3 | 10 | -5 | -1 | 9 | 12 | 8 | 9 | 7 |
| Operating Profit Margin % | -8.00% | -6.00% | 14.00% | -8.00% | -3.00% | 11.00% | 11.00% | 11.00% | 10.00% | 7.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
| Interest | 3 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Profit Before Tax | -13 | -13 | 2 | -13 | -10 | 1 | 4 | 1 | 1 | 0 |
| Tax | 0 | -5 | 2 | 1 | 0 | -2 | 0 | -2 | 0 | -1 |
| Net Profit | -13 | -7 | 0 | -14 | -10 | 3 | 4 | 3 | 1 | 1 |
| Earnings Per Share (₹) | -8.48 | -4.64 | 0.04 | -8.72 | -6.21 | 1.70 | 2.23 | 1.70 | 0.81 | 0.31 |
MANGALAM Balance Sheet — Assets, Liabilities & Shareholders' Equity
MANGALAM total assets ₹315 Cr, total equity ₹103 Cr, total liabilities ₹ Cr (2026) — ROE -12.6%.
| Particulars | 2026 | 2025 | 2024 |
|---|---|---|---|
| ASSETS | |||
| Total Assets | 315 | 366 | 334 |
| Current Assets | 156 | 199 | 176 |
| Fixed Assets | 159 | 163 | 148 |
| Capital Work in Progress | 0 | 3 | 8 |
| Investments | 103 | 0 | 0 |
| Other Assets | 0 | 201 | 178 |
| LIABILITIES | |||
| Total Liabilities | |||
| Current Liabilities | 15 | 26 | 34 |
| Non-Current Liabilities | |||
| SHAREHOLDERS' EQUITY | |||
| Total Equity | 103 | 149 | 136 |
| Share Capital | 16 | 16 | 16 |
| Reserves & Surplus | 87 | 133 | 120 |
MANGALAM Cash Flow Statement — Operating, Investing & Financing
Mangalam Drugs & Organics operating cash flow ₹43 Cr, investing ₹-20 Cr, financing ₹-22 Cr, net cash flow ₹1 Cr (2025).
| Particulars | March 2025 | March 2024 |
|---|---|---|
| Operating Activities | 43 | 4 |
| Investing Activities | -20 | -12 |
| Financing Activities | -22 | 5 |
| Net Cash Flow | 1 | -3 |